20151112 SillaJen_Pexavec_Joint
Category: Press release
Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection
20151103 TG1050 FINAL VERSION US
Transgene Reports Third Quarter 2015 Financial Results
20151021 PR US Q3 2015 FINAL
Transgene to Present at Ladenburg Thalmann 2015 Healthcare Conference in New York
23092015 PR ladenburg conf_EN
Transgene Reports Financial Results for First Six Months of 2015 (interim report)
20150910 – PR 2015 H1 results final
Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
20150908 PR TG4010 IASLC revised – BIS
Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer
19 August 2015_PR_IASLC curtain raiser_ENG
Transgene plans restructuring to focus on research and development
20150629 PR 29 juin fin
Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (poster)
20150601 PR TG4010 TIME results_ASCO 2015_FINAL
Transgene Announces Participation at Upcoming Investor Events
20150518 May thru July 2015 IR events_ver 1 ENG